<DOC>
	<DOCNO>NCT02337751</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety TVP-1012 ( 1 mg/day ) Japanese participant early Parkinson 's disease .</brief_summary>
	<brief_title>A Phase 3 , Long-term , Extension Study TVP-1012 ( 1 mg ) Early Parkinson 's Disease Participants</brief_title>
	<detailed_description>This multicenter , open-label , long-term , extension , phase 3 study evaluate safety efficacy long-term administration TVP-1012 1 mg another 26 week participant early Parkinson 's disease complete precede TVP-1012_CCT_001 study . Among participant TVP-1012_CCT_001 study , consent participate study prior complite precede study fulfil eligibility criterion enrol study . From day Visit 8 precede study , participant receive 1 mg TVP-1012 daily 26 week unblinded manner .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>The participant complete precede study . The participant show safety issue study treatment precede study , opinion investigator subinvestigator . The participant undergone blood collection &gt; = 400 mL within 90 day prior start treatment study . The participant require take excluded medication treatment . The participant require surgery hospitalization surgery study period .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>